Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0M3UT
|
||||
| Former ID |
DNC005671
|
||||
| Drug Name |
MURAGLITAZAR
|
||||
| Synonyms |
Muraglitazar; 331741-94-7; Pargluva; BMS-298585; UNII-W1MKM70WQI; BMS 298585; W1MKM70WQI; CHEMBL186179; N-[(4-Methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine; N-((4-methoxyphenoxy)carbonyl)-N-((4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)glycine; BMS298585; Muraglitazar [USAN:INN]; CCRIS 9258; AC1L4FVP; Muraglitazar (USAN/INN); DSSTox_CID_31508; DSSTox_RID_97393; DSSTox_GSID_57719; SCHEMBL676469; DTXSID9057719; CTK8E8901; MolPort-006-395-259; IRLWJILLXJGJTD-UHFFFAOYSA-N
|
||||
| Drug Type |
Small molecular drug
|
||||
| Structure |
 |
Download2D MOL |
|||
| Formula |
C29H28N2O7
|
||||
| Canonical SMILES |
CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=C(C=C3)CN(CC(=O)O)C(=<br />O)OC4=CC=C(C=C4)OC
|
||||
| InChI |
1S/C29H28N2O7/c1-20-26(30-28(37-20)22-6-4-3-5-7-22)16-17-36-24-10-8-21(9-11-24)18-31(19-27(32)33)29(34)38-25-14-12-23(35-2)13-15-25/h3-15H,16-19H2,1-2H3,(H,32,33)
|
||||
| InChIKey |
IRLWJILLXJGJTD-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 331741-94-7
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Peroxisome proliferator-activated receptor alpha (PPARA) | Target Info | Modulator | [1] | |
| Peroxisome proliferator-activated receptor gamma (PPAR-gamma) | Target Info | Modulator | [1] | ||
| KEGG Pathway | PPAR signaling pathway | ||||
| AMPK signaling pathway | |||||
| Osteoclast differentiation | |||||
| Huntington's disease | |||||
| Pathways in cancer | |||||
| Transcriptional misregulation in cancer | |||||
| Thyroid cancer | |||||
| NetPath Pathway | IL1 Signaling Pathway | ||||
| TGF_beta_Receptor Signaling Pathway | |||||
| Leptin Signaling Pathway | |||||
| Panther Pathway | CCKR signaling map ST | ||||
| Pathway Interaction Database | Noncanonical Wnt signaling pathway | ||||
| Calcineurin-regulated NFAT-dependent transcription in lymphocytes | |||||
| Signaling events mediated by HDAC Class I | |||||
| RXR and RAR heterodimerization with other nuclear receptor | |||||
| Regulation of retinoblastoma protein | |||||
| Reactome | PPARA activates gene expression | ||||
| Transcriptional regulation of white adipocyte differentiation | |||||
| Nuclear Receptor transcription pathway | |||||
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | |||||
| Transcriptional activation of mitochondrial biogenesis | |||||
| Activation of gene expression by SREBF (SREBP) | |||||
| Transcriptional regulation of white adipocyte differentiation | |||||
| Nuclear Receptor transcription pathway | |||||
| Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | |||||
| Circadian Clock | |||||
| WikiPathways | Wnt Signaling Pathway Netpath | ||||
| Nuclear Receptors in Lipid Metabolism and Toxicity | |||||
| Differentiation of white and brown adipocyte | |||||
| Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | |||||
| Transcriptional Regulation of White Adipocyte Differentiation | |||||
| Adipogenesis | |||||
| SREBP signalling | |||||
| Nuclear Receptors | |||||
| Adipogenesis | |||||
| SREBF and miR33 in cholesterol and lipid homeostasis | |||||
| Circadian Clock | |||||
| Nuclear Receptors | |||||
| References | |||||
| REF 1 | Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with... Clin Ther. 2005 Aug;27(8):1181-95. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Wang and Dr. Li.